MEDBOT-B (02252) surged more than 7% once again. As of the time of writing, the stock was up 7.21%, trading at HK$28.26, with a turnover of HK$72.6563 million. The catalyst for the move is the recent issuance of the "Guidelines for the Establishment of Medical Service Price Items for Surgical and Therapeutic Auxiliary Operations (Trial)" by the National Healthcare Security Administration. This document focuses on cutting-edge medical technologies, including 3D printing, surgical robots, and remote surgery, and standardizes 37 price items, 5 additional charge items, and 1 extension item. The aim is to use pricing mechanisms to lead the upgrade of medical technology and promote the transition from "traditional treatment" to "precision medicine." Notably, MEDBOT-B previously announced that, based on the company's internal preliminary statistics, the cumulative volume of comprehensive orders for its core products in laparoscopy, orthopedics, and vascular intervention has exceeded 230 units. Among these, the cumulative global commercial orders for its core product, the Toumai laparoscopic surgical robot (Toumai), have surpassed 160 units, including nearly 120 new orders secured this year. According to publicly available statistics, Toumai's global order volume for 2025 has already ranked second globally.